Skip to main content

Reich Kristian's Form 4 filing

MoonLake Immunotherapeutics (MLTX) · filed Feb 16, 2024

Accession no.
0001213900-24-014996
Filed
Feb 16, 2024
Trade date
Feb 14-16, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market sales total $3.65M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Reich KristianCIK 0001920553Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 14, 2024Class A ordinary shares, par value $0.0001 per shareSSaleDisposed−10,000$62.42−$624,2003,017,483Indirect
Feb 14, 2024Class A ordinary shares, par value $0.0001 per shareSSaleDisposed−10,000$62.43−$624,300130,071Direct
Feb 15, 2024Class A ordinary shares, par value $0.0001 per shareSSaleDisposed−10,000$60.17−$601,7003,007,483Indirect
Feb 15, 2024Class A ordinary shares, par value $0.0001 per shareSSaleDisposed−10,000$60.16−$601,600120,071Direct
Feb 16, 2024Class A ordinary shares, par value $0.0001 per shareSSaleDisposed−10,000$60.15−$601,5002,997,483Indirect
Feb 16, 2024Class A ordinary shares, par value $0.0001 per shareSSaleDisposed−10,000$60.15−$601,500110,071Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)